Lynch Syndrome: Exploring the Potential of mRNA in Cancer Prevention.
Moderna recently received authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for a Phase 1/2 clinical study evaluating mRNA-4194, an investigational mRNA-based vaccine for people with Lynch syndrome, an inherited condition that increases the risk of cancer.
They anticipate the first trial participant to be dosed sometime this summer, this is the first step toward advancing a novel mRNA approach that aims to shift care from treating cancer after its diagnosis to preventing cancer from occurring.
By applying mRNA technology earlier in the patient journey, the goal is to harness the immune system when it could have the greatest impact.
mRNA technology works by instructing cells to produce specific proteins that can train the immune system to recognize and respond to disease. In the case of Lynch syndrome and mRNA-4194, they are investigating whether similar principles could train the immune system, specifically T cells, to detect and eliminate cells that carry these abnormal mutations before they grow into tumours.
This is just at the beginning of this journey, and there will be important insights along the way, deepening understanding of Lynch syndrome and the potential of mRNA technology to address this high unmet need.
https://www.modernatx.com/media-center/all-media/blogs/potential-mRNA-cancer-prevention
Lynch Syndrome Ireland 